Marisa Wexler, MS,  senior science writer—

Treatment with psilocybin — the hallucinogenic agent in magic mushrooms — may help to prevent damage to the brain following mild head injuries, according to a new study done in rats. Head injuries are an established risk factor for Parkinson’s disease, as well as Alzheimer’s and other…

People with dementia related to Parkinson’s disease are at increased risk of death after undergoing surgery to address broken hips, a new study reports. Data suggest this increased risk is higher in people with Parkinson’s-related dementia than other types of dementia. “Our analysis of dementia subtypes reveals that not…

Damage to a part of the brain called the amygdala plays a key role in vision problems for people with Parkinson’s disease, a study suggested. Vision problems are relatively common as people get older. In typical aging, vision problems arise because of issues in the eyes and vision-processing pathways,…

Levels of the protein epidermal growth factor, or EGF, in blood may help predict the risk of cognitive decline in people with Parkinson’s disease, a study reports. The study, “Correlation between plasma epidermal growth factor and follow-up cognitive decline in Parkinson’s disease,” was published in Neurological…

Parkinson’s Revolution, an indoor cycling event to spread awareness about Parkinson’s disease and raise funds for the Parkinson’s Foundation, will take place Feb. 22. The virtual cycling event will feature an indoor cycling ride bracketed by an opening and closing ceremony. There also will be chances for…

The average caregiver for someone with Parkinson’s disease spends more than 30 hours per week doing unpaid work to provide care, and many report substantial emotional and physical strain. That’s according to a new report from the National Alliance for Caregiving (NAC), with support from…

Jupiter Neurosciences said it’s planning a Phase 2a clinical trial to test Jotrol, the company’s oral formulation of resveratrol, as a treatment for Parkinson’s disease, in partnership with Zina Biopharmaceuticals. Zina will assist with aspects of the trial protocol, such as identifying biomarkers and selecting sites for the…

All patients have completed final follow-up visits in a Phase 2 clinical trial testing pirepemat, an oral treatment designed to reduce falls in Parkinson’s disease, and top-line results are expected in the first quarter, said developer Irlab Therapeutics. The development “marks an important milestone in our clinical development program…

Researchers in Italy and Mexico have designed a smart glove that, using sensors, may help to track symptoms and evaluate motor function in people with Parkinson’s disease. The device’s development is described in the study, “A Smart Glove to Evaluate Parkinson’s Disease by Flexible Piezoelectric and…

Aerobic exercise may help relieve non-motor symptoms of Parkinson’s disease in people who have undergone deep brain stimulation (DBS), a small study suggested. The researchers said there’s a need for more studies on exercise and Parkinson’s patients who have had DBS, a surgical treatment that involves implanting an electrode…